Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $19,077.66 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 4,326 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $4.41, for a total value of $19,077.66. Following the sale, the chief executive officer now owns 220,119 shares in the company, valued at $970,724.79. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, December 10th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.20, for a total transaction of $20,500.00.

Lexeo Therapeutics Trading Down 3.5 %

LXEO stock opened at $3.89 on Monday. The company has a market capitalization of $128.64 million, a PE ratio of -1.23 and a beta of 2.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics, Inc. has a 12 month low of $3.84 and a 12 month high of $19.50. The firm’s 50-day moving average is $5.70 and its 200 day moving average is $8.03.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. HC Wainwright raised their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Leerink Partners dropped their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Finally, Chardan Capital increased their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $23.80.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of institutional investors have recently modified their holdings of LXEO. Values First Advisors Inc. purchased a new stake in shares of Lexeo Therapeutics in the third quarter valued at approximately $67,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after buying an additional 33,013 shares during the period. BNP Paribas Financial Markets grew its position in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after buying an additional 7,803 shares in the last quarter. Finally, Vestal Point Capital LP increased its stake in shares of Lexeo Therapeutics by 1.2% during the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after buying an additional 10,000 shares during the period. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.